Chill out: skin cooling may ease pain of NF1 treatments
NCT ID NCT06132165
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether cooling the skin before or during laser and injection treatments for neurofibromatosis type 1 (NF1) skin bumps can reduce pain. Thirteen adults with NF1 received four different treatments (two lasers and two injections) on both cooled and non-cooled skin areas. The main goal was to see if cooling made the procedures more tolerable and safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Skin cooling (ice or cold device) applied before or during laser or injection treatments
- What this could lead to
- If it works, skin cooling could make existing treatments for NF1 skin bumps less painful and more tolerable.
- What could go wrong
- This is a very small Phase 1 study with only 13 people, so results may not apply to everyone. The cooling might not reduce pain enough to matter.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROFIBROMATOSIS 1 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Wellman Center for Photomedicine
Boston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Light-Activated cream could slow growth of NF1 skin tumors
- Antioxidant drug shows promise for kids with NF1
- New drug combo shows promise for rare nerve tumors
- Could a common supplement help kids with NF1 learn and move better?
- New drug combo aims to tame rare childhood leukemia
- New stem cell transplant aims to cut dangerous side effects in blood cancer patients